1355 / 2351
5/30/16
10
TPF: Docetaxel (75 mg/m
2
) + Cisplatin (75 mg/m
2
) + 5-FU (750 mg/m
2
, 120 hours) Q3 weeks
DFHX: Docetaxel + Hydroxyurea + 5FU + Hyperfractionated RT
DeCIDE
R
A
N
D
O
M
I
Z
E
DFHX: Concurrent
Chemoradiotherapy
N2/N3
SCCHN
D
P
F
2 Cycles
D
F
H
X
D
F
H
X
Courtesy of Cohen et al., ASCO 2012
CH-RT >< induction chemo + CH-RT
EHNS-ESTRO H&N course
Florence, June 2016
DeCIDE
Primary Endpoint: Overall Survival
Blue: IC+CRT: n = 142
Red: CRT: n = 138
HR (IC/CRT) =0.91 (0.59, 1.41) p = 0.68
Courtesy of Cohen et al., ASCO 2012
CH-RT >< induction chemo + CH-RT
EHNS-ESTRO H&N course
Florence, June 2016